Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2017

Open Access 01-12-2017 | Consensus article

Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)

Authors: Simona Sacco, Gabriele S. Merki-Feld, Karen Lehrmann Ægidius, Johannes Bitzer, Marianne Canonico, Tobias Kurth, Christian Lampl, Øjvind Lidegaard, E. Anne MacGregor, Antoinette MaassenVanDenBrink, Dimos-Dimitrios Mitsikostas, Rossella Elena Nappi, George Ntaios, Per Morten Sandset, Paolo Martelletti, on behalf of the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)

Published in: The Journal of Headache and Pain | Issue 1/2017

Login to get access

Abstract

Several data indicate that migraine, especially migraine with aura, is associated with an increased risk of ischemic stroke and other vascular events. Of concern is whether the risk of ischemic stroke in migraineurs is magnified by the use of hormonal contraceptives. As migraine prevalence is high in women of reproductive age, it is common to face the issue of migraine and hormonal contraceptive use in clinical practice. In this document, we systematically reviewed data about the association between migraine, ischemic stroke and hormonal contraceptive use. Thereafter a consensus procedure among international experts was done to develop statements to support clinical decision making, in terms of cardiovascular safety, for prescription of hormonal contraceptives to women with migraine. Overall, quality of current evidence regarding the risk of ischemic stroke in migraineurs associated with the use of hormonal contraceptives is low. Available data suggest that combined hormonal contraceptive may further increase the risk of ischemic stroke in those who have migraine, specifically migraine with aura. Thus, our current statements privilege safety and provide several suggestions to try to avoid possible risks. As the quality of available data is poor further research is needed on this topic to increase safe use of hormonal contraceptives in women with migraine.
Literature
1.
Etminan M, Takkouche B, Isorna FC, Samii A (2005) Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies. BMJ 330:63PubMedPubMedCentralCrossRef
2.
Kurth T, Winter AC, Eliassen AH, Dushkes R, Mukamal KJ, Rimm EB, Willett WC, Manson JE, Rexrode KM (2016) Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ 353:i2610PubMedPubMedCentralCrossRef
3.
Sacco S, Ornello R, Ripa P, Pistoia F, Carolei A (2013) Migraine and hemorrhagic stroke: a meta-analysis. Stroke 44:3032–3038PubMedCrossRef
4.
Sacco S, Ornello R, Ripa P, Tiseo C, Degan D, Pistoia F, Carolei A (2015) Migraine and risk of ischaemic heart disease: a systematic review and meta-analysis of observational studies. Eur J Neurol 22:1001–1011PubMedCrossRef
5.
Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T (2009) Migraine and cardiovascular disease: systematic review and meta-analysis. BM 339:b3914CrossRef
6.
Spector JT, Kahn SR, Jones MR, Jayakumar M, Dalal D, Nazarian S (2010) Migraine headache and ischemic stroke risk: an updated meta-analysis. Am J Med 123:612–624PubMedPubMedCentralCrossRef
7.
Androulakis XM, Kodumuri N, Giamberardino LD, Rosamond WD, Gottesman RF, Yim E, Sen S (2016) Ischemic stroke subtypes and migraine with visual aura in the ARIC study. Neurology 87:2527–2532PubMedPubMedCentralCrossRef
8.
Bigal ME, Kurth T, Santanello N, Buse D, Golden W, Robbins M, Lipton RB (2010) Migraine and cardiovascular disease: a population-based study. Neurology 74:628–635PubMedPubMedCentralCrossRef
9.
Carolei A, Marini C, De Matteis G (1996) History of migraine and risk of cerebral ischaemia in young adults. The Italian National Research Council study group on stroke in the young. Lancet 347:1503–1506PubMedCrossRef
10.
Champaloux SW, Tepper NK, Monsour M, Curtis KM, Whiteman MK, Marchbanks PA, Jamieson DJ (2017) Use of combined hormonal contraceptives among women with migraines and risk of ischemic stroke. Am J Obstet Gynecol 216:489.e1–489.e7
11.
Chang CL, Donaghy M, Poulter N (1999) Migraine and stroke in young women: case–control study. The World Health Organization collaborative study of cardiovascular disease and steroid hormone contraception. BMJ 318:13–18PubMedPubMedCentralCrossRef
12.
Haapaniemi H, Hillbom M, Juvela S (1997) Lifestyle-associated risk factors for acute brain infarction among persons of working age. Stroke 28:26–30PubMedCrossRef
13.
Henrich JB, Horwitz RI (1989) A controlled study of ischemic stroke risk in migraine patients. J Clin Epidemiol 42:773–780PubMedCrossRef
14.
Kurth T, Slomke MA, Kase CS, Cook NR, Lee IM, Gaziano JM, Diener HC, Buring JE (2005) Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 64:1020–1026PubMedCrossRef
15.
Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE (2006) Migraine and risk of cardiovascular disease in women. JAMA 296:283–291PubMedCrossRef
16.
Kurth T, Schürks M, Logroscino G, Gaziano JM, Buring JE (2008) Migraine, vascular risk, and cardiovascular events in women: prospective cohort study. BMJ 337:a636PubMedPubMedCentralCrossRef
17.
MacClellan LR, Giles W, Cole J, Wozniak M, Stern B, Mitchell BD, Kittner SJ (2007) Probable migraine with visual aura and risk of ischemic stroke: the stroke prevention in young women study. Stroke 38:2438–2445PubMedCrossRef
18.
Tzourio C, Tehindrazanarivelo A, Iglésias S, Alpérovitch A, Chedru F, d’Anglejan-Chatillon J, Bousser MG (1995) Case–control study of migraine and risk of ischaemic stroke in young women. BMJ 310:830–833PubMedPubMedCentralCrossRef
19.
Schwaag S, Nabavi DG, Frese A, Husstedt IW, Evers S (2003) The association between migraine and juvenile stroke: a case-control study. Headache 43:90–95PubMedCrossRef
20.
Lidegaard Ø, Kreiner S (2002) Contraceptives and cerebral thrombosis: a five year national case–control study. Contraception 65:197–205PubMedCrossRef
21.
Monteith TS, Gardener H, Rundek T, Elkind MSV, Sacco RL (2015) Migraine and risk of stroke in older adults. Northern Manhattan study. Neurology 85:1–7CrossRef
22.
23.
Gillum LA, Mamidipudi SK, Johnston SC (2000) Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA 284:72–78PubMedCrossRef
24.
Baillargeon JP, McClish DK, Essah PA, Nestler JE (2005) Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J Clin Endocrinol Metab 90:3863–3670PubMedCrossRef
25.
Peragallo Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, Myers ER (2013) Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol 122:380–389PubMedCrossRef
26.
Xu Z, Li Y, Tang S, Huang X, Chen T (2015) Current use of oral contraceptives and the risk of first-ever ischemic stroke: a meta-analysis of observational studies. Thromb Res 136:52–60PubMedCrossRef
27.
Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR (2001) The RAND/UCLA appropriateness method user’s manual. RAND Corporation, Santa Monica, CA
28.
Baumann MH, Strange C, Heffner JE, Light R, Kirby TJ, Klein J, Luketich JD, Panacek EA, Sahn SA; AACP Pneumothorax Consensus Group (2001) Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. Chest 119:590–602
29.
Briggs AM, Jordan JE, Ackerman IN, Van Doornum S (2016) Establishing cross-discipline consensus on contraception, pregnancy and breast feeding-related educational messages and clinical practices to support women with rheumatoid arthritis: an Australian Delphi study. BMJ Open 6:e012139PubMedPubMedCentralCrossRef
30.
Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M; Alzheimer's Disease International (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117
31.
32.
Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Zelman Lewis S, Schünemann H (2006) Grading strength of recommendations and quality of evidence in clinical guidelines. Report from an American College of Chest Physicians task force. Chest 129:174–181PubMedCrossRef
33.
Collaborative group for the study of stroke in young women (1975) Oral contraceptives and stroke in young women. Associated risk factors. JAMA 231:718–722CrossRef
34.
Schwartz SM, Petitti DB, Siscovick DS, Longstreth WT Jr, Sidney S, Raghunathan TE, Quesenberry CP Jr, Kelaghan J (1998) Stroke and use of low-dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 29:2277–2284PubMedCrossRef
35.
Albieri V, Olsen TS, Andersen KK (2016) Risk of stroke in migraineurs using triptans. Associations with age, sex, stroke severity and subtype. EBioMedicine 6:199–205PubMedPubMedCentralCrossRef
36.
Lidegaard Ø (1995) Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: the influence of diabetes, hypertension, migraine and previous thrombotic disease. Br J Obstet Gynaecol 102:153–159PubMedCrossRef
37.
Nightingale AL, Farmer RDT (2004) Ischemic stroke in young women. A nested case–control study using the UK general practice research database. Stroke 35:1574–1578PubMedCrossRef
38.
Milhaud D, Bogousslavsky J, van Melle G, Liot P (2001) Ischemic stroke and active migraine. Neurology 57:1805–1811PubMedCrossRef
39.
Pezzini A, Grassi M, Lodigiani C, Patella R, Gandolfo C, Casoni F, Musolino R, Calabrò RS, Bovi P, Adami A, Delodovici ML, Del Zotto E, Rota LL, Rasura M, Del Sette M, Giossi A, Volonghi I, Zini A, Cerrato P, Costa P, Magoni M, Iacoviello L, Padovani A; Italian Project on Stroke in Young Adults Investigators (2011) Predictors of migraine subtypes in young adults with ischemic stroke: the Italian project on stroke in young adults. Stroke 42:17–21
40.
41.
42.
43.
Stang PE, Carson AP, Rose KM, Mo J, Ephross SA, Shahar E, Szklo M (2005) Headache, cerebrovascular symptoms, and stroke: the atherosclerosis risk in communities study. Neurology 64:1573–1577PubMedCrossRef
44.
Donaghy M, Chang CL, Poulter N, on behalf of the European Collaborators of The World Health Organisation Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (2002) Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age. J Neurol Neurosurg Psychiatry 73:747–750
45.
46.
Cologno D, Torelli P, Manzoni GC (1998) Migraine with aura: a review of 81 patients at 10–20 years’ follow-up. Cephalalgia 18:690–696PubMedCrossRef
47.
Eriksen MK, Thomsen LL, Andersen I, Nazim F, Olesen J (2004) Clinical characteristics of 362 patients with familial migraine with aura. Cephalalgia 24:564–575PubMedCrossRef
48.
Eriksen MK, Thomsen LL, Olesen J (2004) New international classification of migraine with aura (ICHD-2) applied to 362 migraine patients. Eur J Neurol 11:583–591PubMedCrossRef
49.
Michel P, Henry P, Letenneur L, Jogeix M, Corson A, Dartigues JF (1993) Diagnostic screen for assessment of the IHS criteria for migraine by general practitioners. Cephalalgia 13(Suppl 12):54–59PubMedCrossRef
50.
Rasmussen BK, Jensen R, Olesen J (1991) Questionnaire versus clinical interview in the diagnosis of headache. Headache 31:290–295PubMedCrossRef
51.
Láinez MJ, Domínguez M, Rejas J, Palacios G, Arriaza E, Garcia-Garcia M, Madrigal M (2005) Development and validation of the migraine screen questionnaire (MS-Q). Headache 45:1328–1338PubMedCrossRef
52.
Kirchmann M, Seven E, Bjornsson A, Bjornssdottir G, Gulcher JR, Stefansson K, Olesen J (2006) Validation of the deCODE migraine questionnaire (DMQ3) for use in genetic studies. Eur J Neurol 13:1239–1244PubMedCrossRef
53.
Fritsche G, Hueppe M, Kukava M, Dzagnidze A, Schürks M, Yoon MS, Diener HC, Katsarava Z (2007) Validation of a German language questionnaire for screening for migraine, tension-type headache, and trigeminal autonomic cephalgias. Headache 47:546–551PubMedCrossRef
54.
Samaan Z, MacGregor EA, Andrew D, McGuffin P, Farmer A (2010) Diagnosing migraine in research and clinical settings: the validation of the structured migraine interview (SMI). BMC Neurol 10:7PubMedPubMedCentralCrossRef
55.
Lipton RB, Dodick D, Sadovsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W, Migraine validation study ID (2003) A self-administered screener for migraine in primary care: the ID migraine validation study. Neurology 61:375–382PubMedCrossRef
56.
Brighina F, Salemi G, Fierro B, Gasparro A, Balletta A, Aloisio A, La Pegna G, Randisi G, Saporito V, Calagna G, La Naia F, Morana R (2007) A validation study of an Italian version of the "ID migraine". Headache 47:905–908PubMedCrossRef
57.
Karli N, Ertas M, Baykan B, Uzunkaya O, Saip S, Zarifoglu M, Siva A; MIRA study group (2007) The validation of ID migraine screener in neurology outpatient clinics in Turkey. J Headache Pain 8:217–223CrossRef
58.
Gil-Gouveia R, Martins I (2010) Validation of the Portuguese version of ID-migraine. Headache 50:396–402PubMedCrossRef
59.
Streel S, Donneau AF, Dardenne N, Hoge A, Bruyère O, Albert A, Guillaume M, Schoenen J (2015) Validation of an extended French version of ID migraine™ as a migraine-screening tool. Cephalalgia 35:437–442PubMedCrossRef
60.
Wang X, San YZ, Sun JM, Zhou HB, Li X, Zhang ZM, Zhao YS, Zhu YL (2015) Validation of the Chinese version of ID migraine in medical students and systematic review with meta-analysis concerning its diagnostic accuracy. J Oral Facial Pain Headache 29:265–278PubMedCrossRef
61.
Eriksen MK, Thomsen LL, Olesen J (2005) The Visual Aura Rating Scale (VARS) for migraine aura diagnosis. Cephalalgia 25:801–810PubMedCrossRef
62.
van Oosterhout WP, Weller CM, Stam AH, Bakels F, Stijnen T, Ferrari MD, Terwindt GM (2011) Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs. Cephalalgia 31:1359–1367PubMedCrossRef
63.
Calhoun AH (2016) Hormonal contraceptives and migraine with aura - is there still a risk? Headache 57:184–193PubMedCrossRef
64.
Roach RE, Helmerhorst FM, Lijfering WM, Stijnen T, Algra A, Dekkers OM (2015) Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke Cochrane Database Syst Rev CD011054
65.
Weill A, Dalichampt M, Raguideau F, Ricordeau P, Blotière PO, Rudant J, Alla F, Zureik M (2016) Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: cohort study. BMJ 353:i2002PubMedPubMedCentralCrossRef
66.
van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC (2005) Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72:168–174PubMedCrossRef
67.
68.
Cole JA, Norman H, Doherty M, Walker AM (2007) Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 109:339–346PubMedCrossRef
69.
Dore DD, Norman H, Loughlin J, Seeger JD (2010) Extended case–control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 81:408–413PubMedCrossRef
70.
Jick SS, Kaye JA, Russmann S, Jick H (2006) Risk of non-fatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg if ethinyl estradiol. Contraception 73:223–228PubMedCrossRef
71.
Jick S, Kaye JA, Li L, Jick H (2007) Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 micrograms of ethinyl estradiol. Contraception 76:4–7PubMedCrossRef
72.
Jick SS, Jick H (2007) The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy 27:218–220PubMedCrossRef
73.
Dinger JC, Heinemann LA, Kühl-Habich D (2007) The safety of a drospirenone-containing oral contraceptive: final results from the European active surveillance study on oral contraceptives based on 142,475 women-years of observation. Contraception 75:344–354PubMedCrossRef
74.
Lidegaard Ø, Lokkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257–2266PubMedCrossRef
75.
Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO (2013) Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users. Contraception 87:93–100
76.
Tepper NK, Dragoman MV, Gaffield ME, Curtis KM (2016) Nonoral combined hormonal contraceptives and thromboembolism: a systematic review. Contraception 95:130–139PubMedCrossRef
77.
Calhoun AH (2012) Combined hormonal contraceptives: is it time to reassess their role in migraine? Headache 52:648–660PubMedCrossRef
78.
Chabbert-Buffet N, Gerris J, Jamin C, Lello S, Lete I, Lobo P, Nappi RE, Pintiaux A (2013) Toward a new concept of "natural balance" in oral estroprogestin contraception. Gynecol Endocrinol 29:891–896PubMedCrossRef
79.
Lidegaard Ø, Milsom I, Geirsson RT, Skjeldestad FE (2012) Hormonal contraception and venous thromboembolism. Acta Obstet Gynecol Scand 91:769–778PubMedCrossRef
80.
Chakhtoura Z, Canonico M, Gompel A, Thalabard JC, Scarabin PY, Plu-Bureau G (2009) Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke 40:1059–1062PubMedCrossRef
81.
Heinemann LA, Assmann A, DoMinh T, Garbe E (1999) Oral progestogenonly contraceptives and cardiovascular risk: results from the transnational study on oral contraceptives and the health of young women. Contracept Reprod Health Care 4:67–73CrossRef
82.
83.
Lidegaard Ø, Nielsen LH, Skovlund CW, Lokkegaard E (2012) Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10. BMJ 344:e2990–e2998PubMedPubMedCentralCrossRef
84.
Petitti DB, Siscovick DS, Sidney S, Schwartz SM, Quesenberry CP, Psaty BM, Raghunathan TE, Koepsell TD, Longstreth WT Jr (1998) Norplant implants and cardiovascular disease. Contraception 57:361–362
85.
Tepper NK, Whiteman MK, Marchbanks PA, James AH, Curtis KM (2016) Progestin-only contraception and thromboembolism: a systematic review. Contraception 94:678–700PubMedCrossRef
86.
Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception (1998) Contraception 57:315–324CrossRef
87.
Dinger J, Minh TB, Heinemann K (2016) Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception 94:328–339PubMedCrossRef
88.
Dinger J, Bardenheuer K, Heinemann K (2014) Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the international active surveillance study of women taking oral contraceptives. Contraception 89:253–263PubMedCrossRef
89.
Merki-Feld GS, Imthurn B, Langner R, Sandor PS, Gantenbein AR (2013) Headache frequency and intensity in female migraineurs using desogestrel-only contraception: a retrospective pilot diary study. Cephalalgia 33:340–346PubMedCrossRef
90.
Merki-Feld GS, Imthurn B, Seifert B, Merki LL, Agosti R, Gantenbein AR (2013) Desogestrel-only contraception reduces headache frequency and improves quality of life in female migraineurs. Eur J Contracept Reprod Health Care 18:394–400PubMedCrossRef
91.
Merki-Feld GS, Imthurn B, Langner R, Seifert B, Gantenbein AR (2015) Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days. J Headache Pain 16:39PubMedCentralCrossRef
92.
Nappi RE, Sances G, Allais G, Terreno E, Benedetto C, Vaccaro V, Facchinetti F (2011) Effects of an estrogen-free, desogestrel-containing oral contraceptive in women with migraine with aura: a prospective diary-based pilot study. Contraception 83:223–228PubMedCrossRef
93.
Nappi RE, Merki-Feld GS, Terreno E, Pellegrinelli A, Viana M (2013) Hormonal contraception in women with migraine: is progestogen-only contraception a better choice? J Headache Pain 14:66PubMedPubMedCentralCrossRef
94.
Morotti M, Remorgida V, Venturini PL, Ferrero S (2014) Progestin-only contraception compared with extended combined oral contraceptive in women with migraine without aura: a retrospective pilot study. Eur J Obstet Gynecol Reprod Biol 183:178–182PubMedCrossRef
95.
Vetvik KG, MacGregor EA, Lundqvist C, Russell MB (2014) Contraceptive-induced amenorrhoea leads to reduced migraine frequency in women with menstrual migraine without aura. J Headache Pain 15:30PubMedPubMedCentralCrossRef
96.
International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodhill A, Green J, Peto J, Plummer M, Sweetland S (2007) Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 370:1609–1621CrossRef
97.
Moreno V1, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S; International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group (2002) Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359:1085–1092
98.
Aegidius K, Zwart JA, Hagen K, Schei B, Stovner LJ (2006) Oral contraceptives and increased headache prevalence: the head-HUNT study. Neurology 66:349–353PubMedCrossRef
99.
Sacco S, Ricci S, Degan D, Carolei A (2012) Migraine in women: the role of hormones and their impact on vascular diseases. J Headache Pain 13:177–189PubMedPubMedCentralCrossRef
100.
Sacco S, Pistoia F, Degan D, Carolei A (2015) Conventional vascular risk factors: their role in the association between migraine and cardiovascular diseases. Cephalalgia 35:146–164PubMedCrossRef
101.
Dunaif A, Thomas A (2001) Current concepts in the polycystic ovary syndrome. Annu Rev Med 52:401–419PubMedCrossRef
102.
de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM (2011) PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 17:495–500PubMedCrossRef
103.
Tomlinson J, Millward A, Stenhouse E, Pinkney J (2010) Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? Diabet Med 27:498–515PubMedCrossRef
104.
Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA (2010) Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the androgen excess and polycystic ovary syndrome (AE-PCOS) society. J Clin Endocrinol Metab 95:2038–2049PubMedCrossRef
105.
Okoroh EM, Hooper WC, Atrash HK, Yusuf HR, Boulet SL (2012) Is polycystic ovary syndrome another risk factor for venous thromboembolism? United States, 2003–2008 Am J Obstet Gynecol 207:377.e1–8
106.
Loder EW, Buse DC, Golub JR (2005) Headache as a side effect of combination estrogenprogestin oral contraceptives: a systematic review. A. J Obstet Gynecol 193:636–649CrossRef
107.
Hanington E, Jones RJ, Amess JAL (1982) Platelet aggregation in response to 5HT in migraine patients taking oral contraceptives. Lancet 1:967–968PubMedCrossRef
108.
Mazal S (1978) Migraine attacks and increased platelet aggregability induced by oral contraceptives. Aust NZ J Med 8:646–648CrossRef
109.
Caballero PE (2009) Migrainous cerebral infarction after postcoital contraception. Cephalalgia 29:691–693PubMedCrossRef
110.
111.
Kim JS, Jung S, Jung YS, Jung MK, Lee JH, Park MK, Hwang SH (2009) A case of ischemic stroke related to the use of emergency contraception. J Neurocrit Care 2:25–27
112.
Rodríguez de Antonio LA, Fuentes B, Aguilar-Amat MJ, Díez-Tejedor E (2011) Emergency contraception and stroke. A new case report. Med Clin (Barc) 136:647–648CrossRef
113.
Sánchez-Guerra M, Valle N, Blanco LA, Combarros O, Pascual J (2002) Brain infarction after postcoital contraception in a migraine patient. J Neurol 249:774PubMedCrossRef
114.
Andersson HM, Siegerink B, Luken BM, Crawley JT, Algra A, Lane DA, Rosendaal FR (2012) High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood 119:1555–1560PubMedCrossRef
115.
Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A (2005) Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 3:1213–1217PubMedCrossRef
116.
Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A (2009) Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 8:998–1005PubMedCrossRef
117.
Wu O, Robertson L, Twaddle S, Lowe GD, Clark P, Greaves M, Walker ID, Langhorne P, Brenkel I, Regan L, Greer I (2006) Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The thrombosis: risk and economic assessment of thrombophilia screening (TREATS) study. Health Technol Assess 10:1–110PubMedCrossRef
118.
Anzola GP, Magoni MD, Guindani M, Rozzini L, Dalla Volta GD (1999) Potential source of cerebral embolism in migraine with aura. A transcranial Doppler study. Neurology 52:1622–1625PubMedCrossRef
119.
Schwedt TJ, Demaerschalk BM, Dodick DW (2008) Patent foramen ovale and migraine: a quantitative systematic review. Cephalalgia 28:531–540PubMedCrossRef
120.
Wilmshurst P, Nightingale S (2001) Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin Sci (Lond) 100:215–220CrossRef
121.
Rundek T, Elkind MS, Di Tullio MR, Carrera E, Jin Z, Sacco RL, Homma S (2008) Patent foramen ovale and migraine: a cross-sectional study from the northern Manhattan study (NOMAS). Circulation 118:1419–1424PubMedPubMedCentralCrossRef
122.
Sacco S, Kurth T (2014) Migraine and the risk of stroke and cardiovascular disease. Curr Cardiol Rep 16:524
123.
Bashir A, Lipton RB, Ashina S, Ashina M (2013) Migraine and structural changes in the brain. A systematic review and meta-analysis. Neurology 81:1260–1268PubMedPubMedCentralCrossRef
124.
Hamedani AG, Rose KM, Peterlin BL, Mosley TH, Coker LH, Jack CR, Knopman DS, Alonso A, Gottesman RF (2013) Migraine and white matter hyperintensities. The ARIC MRI study Neurology 81:1308–1313PubMed
125.
Kurth T, Mohamed S, Maillard P, Zhu YC, Chabriat H, Mazoyer B, Bousser MG, Dufouil C, Tzourio C (2011) Headache, migraine, and structural brain lesions and function: population based epidemiology of vascular ageing-MRI study. BMJ 342:c7357PubMedPubMedCentralCrossRef
126.
Monteith T, Gardener H, Rundek T, Dong C, Yoshita M, Elkind M, DeCarli C, Sacco RL, Wright CB (2014) Migraine, white matter hyperintensities, and subclinical brain infarction in a diverse community. The northern Manhattan study. Stroke 45:1830–1832PubMedPubMedCentralCrossRef
127.
Jousilahti P, Tuomilehto J, Rastenyte D, Vartiainen E (2003) Headache and the risk of stroke: a prospective observational cohort study among 35,056 Finnish men and women. Arch Intern Med 163:1058–1062PubMedCrossRef
128.
Merikangas KR, Fenton BT, Cheng SH, Stolar MJ, Risch N (1997) Association between migraine and stroke in a large-scale epidemiological study of the United States. Arch Neurol 54:362–368PubMedCrossRef
129.
Mosek A, Marom R, Korczyn AD, Bornstein N (2001) A history of migraine is not a risk factor to develop an ischemic stroke in the elderly. Headache 41:399–401PubMedCrossRef
130.
Norton J, Portet F, Gabelle A, Debette S, Ritchie K, Touchon J, Berr C (2016) Are migraine and non-migrainous headache risk factors for stroke in the elderly? Findings from a 12-year cohort follow-up. Eur J Neurol 23:1463–1470PubMedPubMedCentralCrossRef
131.
Tsai CL, Chou CH, Lee PJ, Yin JH, Chen SY, Lin CC, Sung YF, Yang FC, Chung CH, Chien WC, Tsai CK, Lee JT (2016) The potential impact of primary headache disorders on stroke risk. J Headache Pain 17:108PubMedPubMedCentralCrossRef
132.
Yang L, Kuper H, Sandin S, Margolis KL, Chen Z, Adami HO, Weiderpass E (2009) Reproductive history, oral contraceptive use, and the risk of ischemic and hemorrhagic stroke in a cohort study of middle-aged Swedish women. Stroke 40:1050–1058PubMedCrossRef
133.
Bousser MG, Conard J, Kittner S, de Lignieres B, MacGregor EA, Massiou H, Silberstein SD, Tzourio C; International Headache Society Task Force on Combined Oral Contraceptives & Hormone Replacement Therapy (2000) Recommendations on the risk of ischaemic stroke associated with use of combined oral contraceptives and hormone replacement therapy in women with migraine. Cephalalgia 20:155–156
Metadata
Title
Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)
Authors
Simona Sacco
Gabriele S. Merki-Feld
Karen Lehrmann Ægidius
Johannes Bitzer
Marianne Canonico
Tobias Kurth
Christian Lampl
Øjvind Lidegaard
E. Anne MacGregor
Antoinette MaassenVanDenBrink
Dimos-Dimitrios Mitsikostas
Rossella Elena Nappi
George Ntaios
Per Morten Sandset
Paolo Martelletti
on behalf of the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)
Publication date
01-12-2017
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2017
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-017-0815-1

Other articles of this Issue 1/2017

The Journal of Headache and Pain 1/2017 Go to the issue

Research article

Texture features of periaqueductal gray in the patients with medication-overuse headache

Research article

OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study

Research article

The enigma of site of action of migraine preventives: no effect of metoprolol on trigeminal pain processing in patients and healthy controls

Research article

Restless legs syndrome and tension-type headache: a population-based study

Research article

Unveiling the relative efficacy, safety and tolerability of prophylactic medications for migraine: pairwise and network-meta analysis

Review article

Genetic and biochemical changes of the serotonergic system in migraine pathobiology